Suma Babu
Neurology · Boston, MANPI 1750525291
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (55.3%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Biogen accounts for 83.8% of it on its own, with 1 other manufacturer making up the rest. 2025 is the largest year on record at $5,564, more than ten times the $184 reported in 2019.
Across 7 payments — averaging $1112.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$7K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
Across 70 payments — averaging $82,625 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Biogen$5.3M
- Novartis$176K
- Orion Corporation$172K
- Orphai Therapeutics Inc.$59K
- Ionis Pharmaceuticals, Inc.$34K
- Tanabe Pharma America, Inc.$29K
What the payments were for
- Consulting fees$3,30042%
- Speaking & faculty fees$4,30455%
- Food & beverage$1842%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biogen | 5 | $6,528 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $1,260 |
How this compares
$7,788 in reported general payments places this provider in the 75th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 146 | $2,051,983 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 27 | $353,882 |
| NuedextaDextromethorphan Hbr/Quinidine | 79 | $142,042 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 32 | $110,331 |
| Riluzole | 53 | $10,692 |
| Pregabalin | 48 | $2,571 |
| Azathioprine | 14 | $1,580 |
| Atropine Sulfate | 16 | $1,382 |
| Baclofen | 15 | $453 |
| Glycopyrrolate | 15 | $391 |
| Gabapentin | 16 | $300 |
| Escitalopram Oxalate | 13 | $254 |
| Methylprednisolone Sodium SuccMethylprednisolone Sod Succ | 11 | $185 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $140 |
| Sodium Chloride0.9 % Sodium Chloride | 12 | $132 |
Paid to pharmacies, not to this prescriber.
Other neurology in Boston
- Christopher WrightBoston$2.5M
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Pushpa NarayanaswamiBoston$420K
- Roy FreemanBoston$390K
- Michael LevyBoston$387K
- Leeann BurtonBoston$325K
- Ilena GeorgeBoston$316K
- Andrew BudsonBoston$304K
- Denis BalabanBoston$297K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.